Form 4: Eli Lilly Director Acquires Shares Under Deferral Plan

Director Ralph Alvarez acquired 14.246 shares of Eli Lilly & Co common stock under the Lilly Directors' Deferral Plan.

Summary

• Ralph Alvarez, a director of Eli Lilly & Co, acquired 14.246 shares of common stock on March 17, 2025.
• The acquisition was made under the Lilly Directors' Deferral Plan at a price of $824.76 per share.
• These shares were deferred in lieu of cash compensation as stock units and will be settled in shares of common stock following Alvarez's separation from service.
• Following the transaction, Alvarez beneficially owns 54,832.771 shares of Eli Lilly & Co common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects a director's continued investment in the company, suggesting confidence in its future performance. It's a routine transaction, so the impact is limited.

Positives

• The acquisition of shares by a director demonstrates confidence in the company's future.

Future Outlook

The acquired shares will be settled in the future upon the reporting person's separation from service.

Industry Context

This filing is a routine disclosure of a director's stock acquisition, which is common in publicly traded companies as part of executive compensation and alignment of interests.

Comparison to Industry Standards

• Director stock ownership is a common practice among publicly traded companies, such as Johnson & Johnson (JNJ) and Pfizer (PFE), to align executive interests with shareholder value.
• Deferred compensation plans, similar to the Lilly Directors' Deferral Plan, are frequently used by companies like Merck (MRK) and AbbVie (ABBV) to provide long-term incentives to their directors.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment as it reflects a director's investment in the company.

Key Dates

Keywords

Form 4, Director, Share Acquisition, Eli Lilly, LLY, Deferral Plan, Beneficial Ownership, Stock Units